Researchers have determined that a liquid biopsy human papillomavirus DNA test may serve as a useful tool for the diagnosis and surveillance of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).

Quest Diagnostics said it completed its previously announced acquisition of Haystack Oncology.

Inex Innovate of Singapore plans to launch a PCR-based endometrial cancer detection test this summer, following interim results from a clinical study with researchers at the Chinese University of Hong Kong that were presented here at the Association of Molecular Pathology 2023 Europe Congress this week.

China-based, blood cancer early detection and monitoring technology company, SeekIn has released new research on its multi-cancer early detection (MCED) test, OncoSeek.

In the decade since Foundation Medicine first launched its FoundationOne genomic profiling test to look for specific biomarkers in tumor tissue samples, it has racked up dozens of FDA approvals allowing the test to serve as a companion diagnostic for a broad spectrum of cancer drugs.

Pfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc, the drugmaker said late on Tuesday.​

Quest Diagnostics and Haystack Oncology said Thursday that they have reached a definitive agreement for Quest to acquire Haystack for up to $450 million in cash.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

Agena Bioscience and nRichDX said Friday that they have entered a commercial partnership to co-promote their products to researchers developing liquid biopsy applications on Agena's MassArray platform.

Ultima Genomics and Genome Insight said on Monday that they are collaborating to develop affordable whole-genome sequencing testing for cancer patients.